{"id":"W2105562405","doi":"10.1186/2051-1426-2-2","title":"Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Pfizer; Bristol-Myers Squibb; Genentech; Amgen","keywords":"Sorafenib; Medicine; Renal cell carcinoma; Pharmacokinetics; Pharmacodynamics; Pharmacology; Internal medicine; Rash; Oncology; Immunotherapy; Toxicity; Gastroenterology; Hepatocellular carcinoma; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008886141,0.0003296704,0.0009670747,0.0002530779,0.0001890501,0.00004564543,0.0002213582,0.00005953873,0.0001879615],"category_scores_gemma":[0.00004509285,0.0002361915,0.0006592181,0.0001359467,0.00006497029,0.0001149441,0.00001732792,0.0002466317,0.000002496088],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005870063,"about_ca_system_score_gemma":0.0004548087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001559716,"about_ca_topic_score_gemma":0.00004219807,"domain_scores_codex":[0.9978115,0.0001131004,0.0009182455,0.0003060644,0.0004108668,0.0004402462],"domain_scores_gemma":[0.9979981,0.0002434123,0.0006907727,0.0003990627,0.0004959599,0.000172703],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.09548707,0.0140248,0.006172218,0.001450513,0.005208502,0.0001573214,0.01309434,0.0002955338,0.5437751,0.0001318284,0.01330717,0.3068956],"study_design_scores_gemma":[0.2882641,0.1012249,0.008427368,0.0006598341,0.003745272,0.0005680901,0.002994074,0.002158972,0.4443974,0.001694188,0.1449104,0.0009553862],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800443,0.00689602,0.008378622,0.0005421744,0.001228791,0.002697153,0.00003668392,0.00001645758,0.0001598059],"genre_scores_gemma":[0.9903296,0.0002530279,0.004573593,0.0002405898,0.0003552564,0.0005472777,0.00001363136,0.00009563811,0.003591412],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3059402,"threshold_uncertainty_score":0.9631609,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04145423578145745,"score_gpt":0.3631940069784667,"score_spread":0.3217397711970092,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}